Doris Pablo Bustos, MD
Internal Medicine · Washington, DCNPI 1275635559
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 368 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 41 manufacturers reported payments, led by AstraZeneca at 29.6% of the total. Among internal medicine clinicians in DC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 368 payments — averaging $23.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Lilly USA, LLC$1K
- Novo Nordisk$872
- Boehringer Ingelheim$410
- Pfizer$334
- Merck$292
- plus $3K from 35 others
What the payments were for
- Food & beverage$8,50899%
- Education$581%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 87 | $2,539 |
| Lilly USA, LLC | 54 | $1,068 |
| Novo Nordisk | 45 | $872 |
| Boehringer Ingelheim | 15 | $410 |
| Pfizer | 16 | $334 |
| Merck | 17 | $292 |
| Amgen(2 entities) | 10 | $234 |
| Fresenius USA Marketing, Inc. | 11 | $232 |
| Bayer | 11 | $229 |
| Kowa Pharmaceuticals America, Inc. | 6 | $226 |
| GSK | 10 | $195 |
| Akebia Therapeutics Inc | 8 | $168 |
| Mallinckrodt Hospital Products Inc. | 6 | $137 |
| Medtronic | 4 | $135 |
| Vifor Pharma, Inc. | 6 | $131 |
| AbbVie(2 entities) | 6 | $128 |
| Amarin Pharma, Inc. | 5 | $116 |
| Esperion Therapeutics, Inc. | 5 | $113 |
| Mallinckrodt Enterprises LLC | 4 | $97 |
| Sanofi-aventis U.S. LLC | 4 | $83 |
| Edwards Lifesciences | 1 | $71 |
| Arbor Pharmaceuticals, Inc. | 4 | $63 |
| Calliditas Therapeutics US Inc. | 3 | $60 |
| Abbott | 3 | $59 |
| Exact Sciences | 3 | $58 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $53 |
| Dexcom, Inc. | 1 | $52 |
| Johnson & Johnson | 3 | $52 |
| Sanofi Pasteur Inc. | 2 | $42 |
| Smith+Nephew | 2 | $37 |
| OPKO Pharmaceuticals, LLC | 2 | $36 |
| Otsuka America Pharmaceutical, Inc. | 2 | $33 |
| Ardelyx, Inc. | 1 | $30 |
| Novartis | 2 | $29 |
| Aurinia Pharma U.S., Inc. | 1 | $27 |
| E.r. Squibb & Sons, L.L.C. | 1 | $24 |
| Daiichi Sankyo Inc. | 1 | $24 |
| Viiv Healthcare Company | 1 | $22 |
| Sanofi | 1 | $19 |
| Gilead | 1 | $19 |
| Astellas Pharma US Inc | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,566 in reported general payments places this provider in the 90th percentile of 645 internal medicine providers in District of Columbia.
See all internal medicine providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 173 | $177,334 |
| JardianceEmpagliflozin | 115 | $132,773 |
| EliquisApixaban | 102 | $110,368 |
| OzempicSemaglutide | 59 | $71,491 |
| JanuviaSitagliptin Phosphate | 63 | $67,063 |
| TrulicityDulaglutide | 49 | $52,912 |
| JanumetSitagliptin Phos/Metformin Hcl | 40 | $48,605 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $24,455 |
| MounjaroTirzepatide | 26 | $23,661 |
| TradjentaLinagliptin | 28 | $23,174 |
| RybelsusSemaglutide | 23 | $20,725 |
| ProliaDenosumab | 12 | $20,123 |
| EntrestoSacubitril/Valsartan | 18 | $16,816 |
| VascepaIcosapent Ethyl | 20 | $12,761 |
| KerendiaFinerenone | 16 | $12,662 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Symbicort | $2,539 | $183,106194 claims |
| Boehringer IngelheimJardiance, Tradjenta | $410 | $155,947143 claims |
| MerckJanuvia, Janumet | $292 | $115,668103 claims |
| PfizerEliquis | $334 | $110,368102 claims |
| Novo NordiskOzempic, Rybelsus | $872 | $92,21682 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $1,068 | $76,57375 claims |
| GSKTrelegy Ellipta | $195 | $24,45525 claims |
| AmgenProlia | $234 | $20,12312 claims |
| NovartisEntresto | $29 | $16,81618 claims |
| BayerKerendia | $229 | $12,66216 claims |
| Arbor Pharmaceuticals, Inc.Edarbi | $63 | $8,69313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 645 internal medicine providers in District of Columbia.
Other internal medicine in Washington
- Andrea SingerWashington$850K
- Kathryn SowerwineWashington$831K
- Douglas WardWashington$233K
- Geoffrey GibneyWashington$185K
- Kevin GriffithsWashington$180K
- Bruce RashbaumWashington$86K
- Jessica Wang-MemoliWashington$56K
- Dana McGintyWashington$47K
- Geeta NayyarWashington$46K
- Marie BorumWashington$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.